Wall Street has become desensitized to the ongoing turmoil at the U.S. Food and Drug Administration, with a report on May 20, 2026, indicating that biotech investors are tuning out the chaos following the resignation of Commissioner Marty Makary after a tumultuous 13-month tenure.
"While not lacking in reform efforts, Makary’s tenure can be described as chaotic," a STAT News analysis concluded, pointing to mass layoffs, a loss of scientific expertise, and a revolving door of senior officials as key sources of instability.
Under Makary, the FDA pursued an ambitious agenda that included shortening clinical trial timelines by expanding single-study drug approvals and forcing greater transparency by publishing Complete Response Letters. However, his term also saw high-profile departures, including three different heads of the Center for Drug Evaluation and Research in less than a year, and controversial policies that critics argued allowed political priorities to influence the drug approval process.
The market's indifference suggests investors have already priced in the regulatory risk, focusing instead on company-specific fundamentals. The departure of Makary and the appointment of an interim leader, Kyle Diamantas, appears to have a negligible immediate impact on the sector, which remains driven by clinical trial outcomes and financial stability.
A Year of Turmoil
Marty Makary's 13 months as FDA commissioner were among the most disruptive in the agency's recent history. He championed policies aimed at accelerating drug development, making a single robust clinical trial, rather than the traditional two, the default for many novel medicines in oncology and rare diseases. Makary also pushed for the public release of Complete Response Letters, previously confidential notices sent to drugmakers when their applications are rejected.
However, these reforms were overshadowed by internal chaos. Key leaders, including Peter Marks, former head of the Center for Biologics Evaluation and Research, and Richard Pazdur, a longtime FDA veteran, departed citing concerns over Makary's leadership and political meddling. The administration was also criticized for pursuing studies on debunked links between vaccines and autism and promoting questionable dietary guidelines.
Investors Tune Out the Noise
Despite the internal upheaval, biotech investors seem largely unfazed. The sector's focus remains squarely on individual company performance, particularly clinical trial data and financial health. A case in point is Milestone Pharmaceuticals (MIST), whose shares fell after its newly approved nasal spray, Cardamyst, generated only $238,000 in initial sales, far below the $56 million consensus estimate.
However, the market's attention quickly shifted to the company's fundamentals. Milestone reported it has nearly $184 million in cash and short-term investments, providing a sufficient runway into the second half of 2027. This financial cushion allows the company time to ramp up Cardamyst sales and develop it for other indications, an outlook that has tempered concerns over the slow launch.
What's Next for the FDA?
Makary will be temporarily replaced by Kyle Diamantas, the former deputy commissioner for food. Diamantas is a lawyer with no medical training, an unusual profile for an FDA head that adds another layer of uncertainty. While he is expected to maintain the status quo for now, the long-term leadership and policy direction of the agency remain unclear. For now, biotech investors have decided that tracking company balance sheets is more critical than tracking the political drama in Washington.
This article is for informational purposes only and does not constitute investment advice.
